RBC Capital Downgrades ResMed (RMD) to Sector Perform
- Wall St drops as Meta Platforms, economic data weigh
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Dollar firmer on higher U.S. inflation; yen sinks vs euro, US currency
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
CLSA Downgrades ResMed (RMD:AU) (RMD) to Outperform (2), 'High near-term expectations may detract from long-term tailwinds'
August 15, 2022 6:31 AM EDTCLSA analyst Andrew Paine downgraded ResMed (RMD:AU) (NYSE: RMD) from Buy (1) to Outperform (2) with a price target of AUD38.40.
The analyst comments "ResMed (RMD) delivered another solid result in 4Q22, with revenues (ex-Covid at pcp) +10% CC to US$914.7m. This was in-line... More
JPMorgan Downgrades ResMed (RMD) to Neutral
August 12, 2022 9:38 AM EDTJPMorgan analyst David Low downgraded ResMed (NYSE: RMD) from Overweight to Neutral with a price target of $250.00 (from $255.00).
The analyst comments "ResMed is poised to take more market share over coming quarters as its device production ramps up and the key... More